Drugs / 68Ga-NOTA-MAL-Cys39-exendin-4
68Ga-NOTA-MAL-Cys39-exendin-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04185350 | May 2019 → Apr 2020 | pancreatic insulinoma | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-MAL-Cys39-exendin-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185350 ↗ |
| Modality | Diagnostic / imaging agent | “a potential GLP-1R targeted tracer 68Ga-NOTA-MAL-Cys39-exendin-4 for the detection of insulinoma” NCT04185350 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT04185350 ↗ |